Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp WT (LEXXW)

Lexaria Bioscience Corp WT (LEXXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LEXXW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/12/24 [--]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7507 +34.54%
on 06/28/24
1.7400 -41.95%
on 06/13/24
-0.3600 (-26.28%)
since 06/11/24
3-Month
0.5111 +97.61%
on 04/24/24
1.8500 -45.41%
on 06/11/24
+0.1300 (+14.77%)
since 04/11/24
52-Week
0.0500 +1,920.00%
on 10/23/23
2.5000 -59.60%
on 03/11/24
+0.7400 (+274.07%)
since 07/11/23

Most Recent Stories

More News
Lexaria Bioscience (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria Bioscience (NASDAQ: LEXX) Eyeing Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic...

LEXXW : 1.0100 (-3.81%)
LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria Bioscience (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
LLY : 948.40 (+1.53%)
Lexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received two new patent awards, bringing the company’s patent portfolio to 43 granted patents worldwide. According...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria (NASDAQ: LEXX) Announces Commencement of Dosing in GLP-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria Bioscience (NASDAQ: LEXX) Looking to Tap into Various Growing Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption...

LEXXW : 1.0100 (-3.81%)
LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Focusing on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM)...

LEXXW : 1.0100 (-3.81%)
LEXX : 2.79 (-0.71%)
Lexaria (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan,...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar